BACKGROUND: The current 7th edition of the American Joint Committee on Cancer TNM staging system for bladder cancer stages lymph node (LN)-positive disease based on LN location rather than LN size. In addition, common iliac LNs are now considered regional LNs. Whether these changes improve prognostication for node-positive patients, however, remains unclear. OBJECTIVE: To investigate whether the 7th edition of the TNM nodal staging system provides superior prognostication compared with the 6th edition. DESIGN, SETTING, AND PARTICIPANTS: Patients between 2002 and 2008 with LN metastases after radical cystectomy combined with extended or superextended LN dissection were included. Patients were staged using both TNM staging systems. Median follow-up was 54 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier curves were used to estimate overall survival (OS) and recurrence-free survival (RFS). Log-rank tests and Cox proportional hazard regression models were used to test associations of pathologic variables with OS and RFS. RESULTS AND LIMITATIONS: Included were 146 patients with LN metastases of whom 131 patients underwent superextended LN dissection and 15 patients underwent extended LN dissection. Although in the 7th TNM edition many patients moved from the N2 category to the N3 category, RFS did not significantly differ within the nodal subgroups in either editions. LN metastases at or above the aortic bifurcation were not associated with decreased RFS (p=0.67). On multivariable analysis, the presence of extravesical disease (hazard ratio [HR]: 2.84; p=0.002), absence of adjuvant chemotherapy (HR: 0.32; p<0.0001), and more than six positive LNs (HR: 2.72; p=0.007) were associated with decreased RFS. This was a retrospective study with inherent limitations. CONCLUSIONS: LNs at or above the aortic bifurcation should be considered regional LNs. Neither the 6th nor the 7th TNM staging system performed well as a prognostic tool. A better staging system for LN-positive bladder cancer needs to be developed.
BACKGROUND: The current 7th edition of the American Joint Committee on Cancer TNM staging system for bladder cancer stages lymph node (LN)-positive disease based on LN location rather than LN size. In addition, common iliac LNs are now considered regional LNs. Whether these changes improve prognostication for node-positive patients, however, remains unclear. OBJECTIVE: To investigate whether the 7th edition of the TNM nodal staging system provides superior prognostication compared with the 6th edition. DESIGN, SETTING, AND PARTICIPANTS: Patients between 2002 and 2008 with LN metastases after radical cystectomy combined with extended or superextended LN dissection were included. Patients were staged using both TNM staging systems. Median follow-up was 54 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Kaplan-Meier curves were used to estimate overall survival (OS) and recurrence-free survival (RFS). Log-rank tests and Cox proportional hazard regression models were used to test associations of pathologic variables with OS and RFS. RESULTS AND LIMITATIONS: Included were 146 patients with LN metastases of whom 131 patients underwent superextended LN dissection and 15 patients underwent extended LN dissection. Although in the 7th TNM edition many patients moved from the N2 category to the N3 category, RFS did not significantly differ within the nodal subgroups in either editions. LN metastases at or above the aortic bifurcation were not associated with decreased RFS (p=0.67). On multivariable analysis, the presence of extravesical disease (hazard ratio [HR]: 2.84; p=0.002), absence of adjuvant chemotherapy (HR: 0.32; p<0.0001), and more than six positive LNs (HR: 2.72; p=0.007) were associated with decreased RFS. This was a retrospective study with inherent limitations. CONCLUSIONS: LNs at or above the aortic bifurcation should be considered regional LNs. Neither the 6th nor the 7th TNM staging system performed well as a prognostic tool. A better staging system for LN-positive bladder cancer needs to be developed.
Authors: Thomas Horn; Sebastian C Schmid; Anna K Seitz; Jessica Grab; Petra Wolf; Bernhard Haller; Margitta Retz; Tobias Maurer; Michael Autenrieth; Hubert R Kübler; Jürgen E Gschwend Journal: World J Urol Date: 2014-07-10 Impact factor: 4.226
Authors: Marisa M Clifton; Sarah P Psutka; Stephen A Boorjian; John C Cheville; Prabin Thapa; R Houston Thompson; Matthew K Tollefson; R Jeffrey Karnes; Igor Frank Journal: World J Urol Date: 2014-05-15 Impact factor: 4.226
Authors: Karla J Lindquist; Thomas Sanford; Terence W Friedlander; Pamela L Paris; Sima P Porten Journal: PLoS One Date: 2017-11-15 Impact factor: 3.240
Authors: Sajjad Mohammad Ganji; Massoud Saidijam; Razieh Amini; Seyed Habibollah Mousavi-Bahar; Nooshin Shabab; Saman Seyedabadi; Ali Mahdavinezhad Journal: Int J Mol Cell Med Date: 2017-07-08